A recent study explored in a group of prostate cancer patients undergoing androgen deprivation therapy the possible impact of TP53 mutations on patient prognosis, showing that only alteration in TP53, but not in AR, was an independent predictor of poor prognosis when compared with clinical covariates [299]. This evidence concerns the gene AR and prostate cancer.